ELI LILLY & Co (LLY)
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - General
Eli Lilly and Company
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 941.36M shares outstanding
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world.
Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Leadership
Anat Hakim
Executive Vice President, General Counsel & Secretary
Carolyn R. Bertozzi, Ph.D.
Dan Skovronsky, M.D., Ph.D.
Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs
Dave Ricks
Chair, President, and Chief Executive Officer
Employees
50K+
Country
US
Sector
Healthcare
Website
lilly.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Grant/Award | 3.998 | $5.0K | Oct 19, 2026 | |
| Director | Grant/Award | 12.833 | $15.9K | Oct 19, 2026 | |
| Director | Grant/Award | 10.011 | $12.4K | Oct 19, 2026 | |
| Director | Grant/Award | 7.995 | $9.9K | Oct 19, 2026 | |
| Director | Grant/Award | 13.664 | $15.9K | Sep 21, 2026 | |
| Director | Grant/Award | 10.659 | $12.4K | Sep 21, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
LILLY ENDOWMENT, INC. · may incl. warrants· filed Oct 2026 | 90.1M | 9.6% | 13G |
BlackRock, Inc. | 67.5M | 7.2% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jan 2024 | 64.4M | 6.8% | 13G |
VANGUARD CAPITAL MANAGEMENT LLC | 53.5M | 5.7% | 13F |
PNC FINANCIAL SERVICES GROUP, INC. | 51.3M | 5.5% | 13F |
THE PNC FINANCIAL SERVICES GROUP, INC. · also on 13F· may incl. warrants· filed Feb 2025 | 51.2M | 5.4% | 13G |
STATE STREET CORP | 36.2M | 3.8% | 13F |
FMR LLC | 28.5M | 3.0% | 13F |
Capital Research Global Investors | 20.9M | 2.2% | 13F |
VANGUARD PORTFOLIO MANAGEMENT LLC | 20.9M | 2.2% | 13F |
Insiders
- Sulzberger GabrielleDirector
- LUCIANO JUAN RDirector
- Alvarez RalphDirector
- Fyrwald J ErikDirector
- Seymour MelissaEVP, Global Quality
- Hernandez EdgardoEVP & Pres., Mfg. Operations
- Dozier EricEVP, Chief People Officer
- Jonsson PatrikEVP & President, LLY Int'l
- Zakrowski Donald ASVP, Finance, & CAO
- Hakim AnatEVP, GC & Secretary
based on 941.36M shares outstanding
30d Avg
2.32M
60d Avg
2.34M
90d Avg
2.51M